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Abstract 
We characterized the role of the three exoplasmic loops in the transmembrane r gion of the thyrotropin receptor (TSHR) by substituting each 
loop with the counterpart of&adrenergic receptor amino acid sequence. Mutant El3 with a substitution of the 3rd exoplasmic loop showed significant 
decrease in the maximal evel and sensitivity of TSH-stimulated CAMP response despite good retention of TSH binding. These findings suggest hat 
the third exoplasmic loop of the TSH receptor is partially involved in the signal transduction mechanism. 
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1. Introduction 
The thyrotropin receptor (TSHR) as well as gona- 
dotropin receptors have a long amino-terminal extracel- 
lular domain which is postulated to confer ligand bind- 
ing specificity, and a carboxyl-terminal transmembrane 
domain with 7 transmembrane spanning helices which 
directly regulates ignal transduction activity [l-8]. How 
such receptors are activated by a ligand which initially 
binds to the extracellular domain is of interest in terms 
of the structural characteristics of this class of receptors. 
This is because 7 transmembrane receptors for small 
ligands such as amines, short peptides, chemical 
odorants and light photons, have been known to bind the 
ligands on the outer surface of their transmembrane re- 
gion to directly change their conformation and activate 
guanine nucleotide binding (G) proteins [9]. There is a 
speculation that ligand/extracellular domain complex or 
the extracellular domain which has been conformation- 
ally changed by ligand binding, contacts the outer sur- 
face of the transmembrane domain to activate the recep- 
tor [4]. To clarify this possibility and to examine the roles 
of the exoplasmic loops, we made substitution mutants 
involving individual exoplasmic loops of the TSH recep- 
tor, transfected the mutants into Cos-7 cells and meas- 
ured TSH binding and cAMP/inositol phosphate re- 
sponses. 
2. Materials and methods 
2.1. Mutagenesis 
Oligonucleotide-mediated, site-directed mutagenesis was used to cre- 
ate the mutants as previously described [lo,1 11. 
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2.2. Transfection 
Transfection of Cos-7 cells with mutant or wild type (WT) TSHR or 
pSG5 vector DNA was performed by electroporation [lO,ll]; 25 pg 
purified plasmid DNA was used in each. To evaluate transfection effi- 
ciency, pSVGH was co-transfected with mutant or WT TSHR or pSG5 
vector cDNA. Aliquots of the same batch of transfected cells were 
plated for Northern blot, Western blot, TSH binding and cAMP/inos- 
itol phosphate assay; medium was inositol-free in the latter assays and 
supplemented with 2.5 pCi/ml myo-[2-‘H(N)]inositol (DuPont-NEN, 
Boston, MA). 
2.3. Assays 
All the assays were initiated simultaneously 48 h after transfection 
[lO,l l] and after washing with assay buffer: NaCl-free, Hanks’ 
Balanced Salt Solution containing 0.5% BSA, 222 mM sucrose, and 
20 mM HEPES at pH 7.4. [‘“51]TSH binding was measured after incu- 
bation for 2 h at 22°C in 1 ml of assay buffer containing [‘*‘I]TSH and 
0 to lo-’ M unlabeled TSH. Specific binding was obtained by subtract- 
ing values obtained in the presence of lo-’ M unlabeled TSH. Total 
CAMP and inositol phosphate levels were measured in the same wells 
after incubation for 1 h at 37°C with 0.2 ml assay buffer containing 
10 mM LiCl, 0.5 mM 3-isobutyl-l-methylxanthine, and, as noted, IO-” 
to lo-’ M TSH, or 10pM ATP. Total CAMP was measured by radioim- 
munoassay and inositol phosphate formation was determined using 
anion exchange columns. 
All assays were performed in duplicate, on at least 3 separate occa- 
sions with different baths of cells, and with simultaneously run positive 
and negative controls: cells transfected with WT or pSG5 vector alone. 
Values in each well were corrected for cell protein. The program 
LIGAND [12] and a single high affinity site model were used to calcu- 
late Kd values for TSH binding and EC,, values for TSH-increased 
inositol phosphate and CAMP levels. 
GH concentration of cultured media of cells used for the assays was 
determined by RIA. Northern blot of RNA from transfected Cos-7 cells 
was done as previously described [10,l l] using total RNA and WT, full 
length rat TSHR cDNA probe. 
2.4. Western blot 
Western blots of membrane proteins derived from an aliquot of 
Cos-7 cells transfected with WT or mutant receptor cDNA and used 
for the assays described above were performed as described [13]. 
2.5. Statistics 
All values in Table 1 are presented as means f S.E.M. from multiple 
experiments as noted (Table 1). Student’s t-test was used for statistical 
analyses. As for Kd and ECSo, statistical differences are calculated using 
log-transformed values. 
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3. Results 
We created mutants involving one of the three 
exoplasmic loops in the transmembrane r gion of the rat 
TSHR by substituting with the counterpart residues 
from human &adrenergic receptor (AR) (Fig. 1) [14]. 
The longest exoplasmic loop, the 2nd loop, is divided 
into amino- and carboxyl-segments and the &AR se- 
quence was substituted in each segment; E12N-1 and 
E12C-1. E12N-2 and E12C-2 were obtained by chance 
during mutagenesis and tested as well. The mutants are 
designed not to change the cysteine residues (Cys-494 in 
the 1st exoplasmic loop and Cys-569 in the 2nd loop; 
residue numbers are counted from methionine start site) 
conserved among most receptors with 7 transmembrane 
helices [9]. These cysteines are postulated to be involved 
in the three-dimensional structure such as disulfide bond 
formation because the point mutations of the cysteines 
lost all functional activities [ 151. Substitution mutants 
involving the 1st or 3rd exoplasmic loop are designated 
as El1 and E13, respectively. The same designation is 
used to describe the mutant cDNA itself and the Cos-7 
cells transfected with the mutant cDNA. 
To accurately compare functional activities among 
transfectants, cells were transfected by electroporation in 
batches, and aliquots from one transfectant were used 
for GH measurement, Northern and Western blots, TSH 
binding and cAMP/inositol phosphate assays simultane- 
ously. The transfection efficiency, determined by co- 
transfecting 0.1 ,ug pSVGH and measuring the GH con- 
centrations in the culture media, was always within 
2 14% of the mean. The mRNA in Cos-7 cells trans- 
fected with the mutants, estimated by Northern analysis 
of the total RNA was identical in size and similar in 
Table 1 
Summary of mutant activities 
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474 493 
WT 8VDLYHTEYYNHAIDWQTGPGON 
El1 8VI:ILr~ I 84 I I 11 II . II wuc~tf MUUIN 
-360343 500570 519ma 
WT ISSYAK---VSIOLPYDTDTPL-A-LA 
E 12N- 1 188MAk@f!~~LPYDTDTDTPL-A-LA 
El 2N-2 R~S~~~B~LPMDTDTPL-A-LA 
E 12 C- 1 18 SYAK---V8 I Cb’4~M#mfmXBMULA 
ElBC-2 188YAK---VSIC~~~~~~~~ 
WT LM?!KPLIT!i?iN8 
El3 LM~JBZiLI~N8 
Fig. 1. Amino acid sequence of each substitution mutant involving one 
of exoplasmic loop of the rat TSH receptor (TSHR). The boxed resi- 
dues detail the sequence change; these are from human /I,-adrenergic 
receptor amino acid sequence (14). (-) indicates no corresponding 
amino acid. 
amount (within k 22% of the mean) to that from cells 
transfected with full-length WT TSHR cDNA. All the 
mutants exhibited the same profile and a similar amount 
of TSHR forms on Western blot of membrane prepara- 
tions from the cells (Fig. 2). Thus, similar amounts of the 
three major TSHR forms, 230, 180 and 95 kDa, were 
identified in three independent experiments using differ- 
ent batches of transfected cells. 
Ten PM ATP increased inositol phosphate levels 
3.7 I!I O.Cfold (mean + S.E.M.) in Cos-7 cells transfected 
with WT. Every mutant transfectant exhibited essentially 
the same response to ATP (data not shown), indicating 
that the inositol phosphate response to TSH is TSHR 
specific. 
Mutant pSG5 WT El1 E12N-1 E12N-2 E12C-1 E12C-2 El3 
TSH binding 
K+ (PM) _ 213+23 ND’ llfl** ND ND ND 23 f 6** 
%&,, (NT) _ 100 ND 9&l** ND ND ND 28 f 3** 
CAMP increase 
ECso @M) _ 125f 18 NR’ 54f 16 NR NR NR 435 + 17* 
% Basal (/pSGS) 100 294 + 26 153 + 25** 126 f 9** 120 * 20** 84f 12 107 + 10** 213 f 51 
Max Resp (/pSGS)+ _ 17.8 f 1.2 - 12.4 f 2.3 ~ _ 7.4 k 0.4** 
Max Resp (/basal)* _ 6.0 + 0.7 - 9.8 f l.l* - _ _ 3.4 f 0.4** 
IPn increase 
ECo (&M) _ 571 k62 NR 921 f 198 NR NR NR 1100 f 290 
% Basal (/pSGS) 100 96 + 2 111+9 100f 8 99 + 7 102 f 3 90 f 6 92 f 4 
Max Resp (/pSGS)’ _ 3.3 kO.2 - 1.8 + 0.2* - _ 1.5 f 0.2** 
Number of experiments 9 9 3 3 3 3 3 3 
Values are expressed as means + S.E.M. of all experiments whose numbers are shown in the bottom line. 
+ Not detectable. 
’ Non-responsive. 
** Statistically signilicant difference from WT (P < 0.01). 
* Statistically significant difference from WT (P < 0.05). 
+ Maximal response compared with the basal level of pSG5 transfectant (fold). 
* Maximal response compared with the basal level of each mutant transfectant (fold). 
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3.1. Functional activities of mutant receptors 
As shown in Table 1, Eli, E12N-2, E12C-1 and E12C-2 
did not show any measurable TSH binding despite of 
similar protile in Western blot to that of WT. These 
mutant transfectants exhibited no TSH-stimulated 
CAMP or inositol phosphate increase. Graves’ IgGs did 
not stimulate CAMP or inositol phosphate increase either 
(data not shown). Basal CAMP and inositol phosphate 
levels were also similar to pSG5 control transfectant 
level. 
E12N-1 and El3 exhibited a significantly decreased 
&kXX for TSH binding compared with WT. There was 
however, a significant increase in the affinity. 
In E12N-1, the EC,, for TSH-CAMP assays was not 
statistically different from that of WT. The maximal re- 
sponse relative to the level in the pSG5 control transfec- 
tant was not different significantly from that of WT. 
When compared with the basal CAMP level of the same 
transfectant, the maximal response was rather better 
than that of WT, because the basal CAMP level of 
E12N-1 was decreased to the pSG5 level (Fig. 3B). Thus, 
WT increased the basal CAMP level compared with the 
pSG5 control transfectant as previously described [lo]. 
On the other hand, the maximal TSH-induced inositol 
phosphate response was significantly decreased, al- 
though the ECso was not significantly different from that 
of WT (Fig. 3C and Table 1). 
In E13, the EC,, in the TSH-stimulated CAMP re- 
sponse was slightly (3.5-fold) but significantly increased. 
Further, the maximal TSH-CAMP response whether 
compared with the pSG5 control level or with the basal 
level of the same transfectant, was significantly de- 
creased. The basal CAMP level without agonist stimula- 
tion was not significantly decreased from WT in contrast 
to E12N-1. Although the ECso in the TSH-stimulated 
kDa 
+ 230 
- 180 
- 95 
Fig. 2. Western blot of TSHR forms in membranes from Cos-7 cells 
transfected with 25 pg wild-type or mutant TSHR or pSG5 vector 
DNA. 
inositol phosphate increase was not significantly differ- 
ent from that of WT, the maximal response was signifi- 
cantly decreased. 
4. Discussion 
Only 2 out of the 6 mutants created in this series had 
specific TSH binding. Although E12N-1 exhibited a very 
low (l/l 1 of WT) TSH binding B,,, the CAMP response 
was fairly well retained. It should be noted that WT 
transfectant with l/8 B_ of usual transfectant by de- 
creasing the amount of DNA for transfection only 
showed a 6.8-fold maximal CAMP increase from the 
pSG5 basal level [lo]. Thus, the effects of the E12N-1 
mutation, including those upon the inositol phosphate 
-Lcg(Tctcl TSH Cent.(U)) -Log(TSH Cont.(M)) -Log(TSH Cone.&)) 
Fig. 3. Displacement of [“‘I]TSH binding by unlabeled TSH (A) and the ability of TSH to increase CAMP (B) and inositol phosphate formation 
(C) in Cos-7 cells transfected with wild-type (WT) and mutants involving the exoplasmic loop (E12N-1 and E13) (Fig. 1). In A, data are from a single 
experiment performed in duplicate. Essentially identical results were obtained in at least 3 separate xperiments. The & and B,,, values determined 
by the program LIGAND [7] are noted in Table 1 and are the means (5 S.E.M.) of all experiments. In B and C, each point is the mean f S.E.M. 
of all experiments, the number of which is noted in Table 1. In each case, data are from cells transfected with 25 pug cDNA, including cells harboring 
the pSG5 vector alone. TSH had no e!%t on CAMP or inositol phosphate formation in control cells transfected with pSG5. 
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response are attributed to the effect of the decreased 
B nxw.~ and a direct effect of the 2nd exoplasmic loop of 
the TSHR on signal transduction seems less likely. 
In contrast, El3 with a substitution of the third 
exoplasmic loop, had a 3-times larger B,_ than E12N-1, 
but an apparently lower maximal response and a higher 
ECso in the TSH-CAMP assay and a smaller maximal 
inositol phosphate response. These results indicate that 
the third exoplasmic loop is important, at least in part, 
for CAMP and inositol phosphate responses. It should be 
noted that El3 has only 5 amino acids substituted and is 
the least different from WT among all the mutants cre- 
ated in this series. Because the exoplasmic loops cannot 
directly interact with G proteins which locate on the 
inner surface of the plasma membrane, the 3rd exoplas- 
mic loop might intact with ligand/extracellular domain 
complex. 
However, 4 other mutants did not give us any informa- 
tion. They totally lost TSH binding as well as CAMP/ 
inositol responses although the Western blots showed 
these mutants were fully glycosylated. Similar TSHR 
mutations made by others which had lost all functional 
activities, were not able to provide any informative evi- 
dence about signal transduction either [16]. These muta- 
tions probably confer deleterious effects on the entire 
three-dimensional structure of the TSHR molecule. 
The extracellular domain of the TSHR is the primary 
binding site of TSH [17,18], as it is with gonadotropins 
and gonadotropin receptors. Mutant lutropin/choriogo- 
nadotropin receptors (LH/CHR) without entire extracel- 
lular domain bound hCG with low affinity [19]. It is not 
clear whether TSH binds to the transmembrane region 
of the receptor with low affinity, because TSH also binds 
to the cells without TSHR with low affinity (& = -lo-’ 
M) [20]. However, this does not exclude the possibility 
that there are two kinds of TSH binding sites (high affin- 
ity/low affinity). How does TSH bind to the extracellular 
domain activate the receptor and promote G protein 
coupling? One possibility is that a conformational 
change of the extracellular domain caused by the binding 
of TSH is directly transmitted to the transmembrane 
region which interacts with G proteins, Another is that 
some contact between TSH/extracellular domain com- 
plex and the outer surface of the transmembrane domain 
is necessary to cause a conformational change of the 
transmembrane domain. 
Our present findings on the mutant involving the 3rd 
exoplasmic loop suggest that the latter is more likely 
because the former notion, direct transmission without 
contact between TSH/extracellular domain complex and 
the transmembrane domain fails to explain the present 
results. 
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Ji et al. have reported that mutations of Asp-397 in the 
first exoplasmic loop of the LH/CGR totally impair the 
CAMP response without affecting human CG binding 
[21,22]. Because this Asp is conserved among all 
glycoprotein hormone receptors [9], not only the third 
loop but also the first exoplasmic loop of this class of 
receptors seems to play an important role in signal 
transduction. 
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